Headquartered in Antwerp, Belgium, with an additional site in Denmark (Aarhus). The company is developing macrophage-targeted ...

Vinay Prasad, director of the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER), ...

GSK (LSE: GSK) has chosen to unwind its synthetic lethality alliance with US biotech Ideaya Biosciences (Nasdaq: IDYA), ...

The European Commission has approved Roche’s Gazyva/Gazyvaro (obinutuzumab) in combination with mycophenolate mofetil (MMF) ...

Sanegene Bio has raised more than $110 million in a series B round to move its RNAi programs toward registration studies and ...

Roche (ROG: SIX) has unveiled a fresh wave of data for Lunsumio (mosunetuzumab), underscoring the Swiss pharma major’s ...

China is making significant strides in CAR-T innovation. Recently, Chongqing Precision Biotech received approval for Priligy ...

Kallyope is preparing to move its oral migraine candidate elismetrep toward registrational development after the TRPM8 ...

Ascletis Pharma (HKEX: 1672) has reported positive topline results from a 13-week Phase II study of ASC30, its once-daily oral GLP-1 agonist for obesity. All three doses met the primary endpoint with ...

Privately-held UK biotech Relation Therapeutics has announced a multi-program, strategic collaboration with Swiss pharma giant Novartis to discover and advance novel targets for atopic diseases.

Italian pharma major Recordati’s rare diseases subsidiary announced the presentation of new data detailing advances in the ...

The cell and gene therapy (CGT) sector is undergoing a transition as companies navigate a more selective and strategy-driven ...